INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
INOVATYON/ENGOT-ov5 研究:一项随机 III 期国际研究,比较曲贝替定/聚乙二醇化脂质体阿霉素 (PLD) 序贯铂类化疗与卡铂/PLD 方案治疗复发性卵巢癌(末次铂类化疗后 6-12 个月内进展)患者的疗效。
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-022-02108-7
Colombo, N; Gadducci, A; Sehouli, J; Rulli, E; Mäenpää, J; Sessa, C; Montes, A; Ottevanger, N B; Berger, R; Vergote, I; D'Incalci, M; Churruca Galaz, C; Chekerov, R; Nyvang, G B; Riniker, S; Herbertson, R; Fossati, R; Barretina-Ginesta, M P; Deryal, M; Mirza, M R; Biagioli, E; Iglesias, M; Funari, G; Romeo, M; Tasca, G; Pardo, B; Tognon, G; Rubio-Pérez, M J; DeCensi, A; De Giorgi, U; Zola, P; Benedetti Panici, P; Aglietta, M; Arcangeli, V; Zamagni, C; Bologna, A; Westermann, A; Heinzelmann-Schwarz, V; Tsibulak, I; Wimberger, P; Poveda, A